ArticleBritish journal of cancer2001
Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- A new drug combination significantly reduces kidney tumor progression in kidney mouse model.Oncotarget · 2018Article
- Tuberous sclerosis complex: the past and the future.Pediatric nephrology (Berlin, Germany) · 2015Review
- Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.American journal of respiratory and critical care medicine · 2015Article
- Tuberin-deficiency downregulates N-cadherin and upregulates vimentin in kidney tumor of TSC patients.Oncotarget · 2014Article
- Evidence for aldosterone-dependent growth of renal cell carcinoma.International journal of experimental pathology · 2014Article
- Novel mechanism of regulation of fibrosis in kidney tumor with tuberous sclerosis.Molecular cancer · 2013Article
- State of the science: an update on renal cell carcinoma.Molecular cancer research : MCR · 2012Review
- Renal cancer: oxygen meets metabolism.Experimental cell research · 2012Review
- Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.American journal of nuclear medicine and molecular imaging · 2012Article
- Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.Molecular cancer research : MCR · 2011Article
- Novel mechanism of regulation of the DNA repair enzyme OGG1 in tuberin-deficient cells.Carcinogenesis · 2010Article
- The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin.The American journal of pathology · 2010Article
- Tuberous sclerosis complex: a brave new world?Current opinion in neurology · 2010Review
- Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway.Cell cycle (Georgetown, Tex.) · 2009Review
- Gastric Adenocarcinoma in Association with Tuberous Sclerosis: Case report.Sultan Qaboos University medical journal · 2009Article
- Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients.Molecular cancer · 2009Article
- Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.Human molecular genetics · 2008Article
- Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.BMC cancer · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genetic events involved in the aetiology of non-clear-cell renal cell carcinoma (RCC) and a proportion of clear cell RCC remain to be defined. Germline mutations of the TSC1 and TSC2 genes cause tuberous sclerosis (TSC), a multi-system hamartoma syndrome that is also associated with RCC. We assessed 17 sporadic clear cell RCCs with a previously identified VHL mutation, 15 clear-cell RCCs without an identified VHL mutation and 15 non-clear-cell RCCs for loss of heterozygosity (LOH) at chromosomes 9q34 and 16p13.3, the chromosomal locations of TSC1 and TSC2. LOH was detected in 4/9, 1/11 and 3/13 cases informative at both loci. SSCP analysis of the whole coding region of the retained allele did not reveal any cases with a detectable intragenic second somatic mutation. Furthermore, RT-PCR analysis of TSC1 and TSC2 on total RNA from 8 clear-cell RCC cell lines confirmed expression of both TSC genes. These data indicate that biallelic inactivation of TSC1 or TSC2 is not frequent in sporadic RCC and suggests that the molecular mechanisms of renal carcinogenesis in TSC are likely to be distinct.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.